US 12,357,712 B2
Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy
Fan Wang, Beijing (CN); Jiyun Shi, Beijing (CN); Hannan Gao, Beijing (CN); and Bing Jia, Beijing (CN)
Assigned to Beijing Giluntide Pharmaceutical Co., Ltd., Beijing (CN)
Appl. No. 17/310,604
Filed by Beijing Giluntide Pharmaceutical Co., Ltd., Beijing (CN)
PCT Filed May 22, 2020, PCT No. PCT/CN2020/091861
§ 371(c)(1), (2) Date Aug. 12, 2021,
PCT Pub. No. WO2020/238800, PCT Pub. Date Dec. 3, 2020.
Claims priority of application No. 201910441556.7 (CN), filed on May 24, 2019; and application No. 202010373843.1 (CN), filed on May 6, 2020.
Prior Publication US 2023/0117927 A1, Apr. 20, 2023
Int. Cl. A61K 51/08 (2006.01); A61P 35/00 (2006.01); C07B 59/00 (2006.01); C07K 7/64 (2006.01)
CPC A61K 51/082 (2013.01) [A61K 51/088 (2013.01); A61P 35/00 (2018.01); C07B 59/004 (2013.01); C07K 7/64 (2013.01)] 14 Claims
 
1. A radionuclide-labelled polypeptide complex that is 177Lu-DOTA-A-L-3PRGD2 having a structural formula of

OG Complex Work Unit Chemistry